How should investors evaluate Repligen Corporation (NASDAQ:RGEN)?

In yesterday’s Wall Street session, Repligen Corporation (NASDAQ:RGEN) shares traded at $175.29, up 2.70% from the previous session.

As of this writing, 12 analysts cover Repligen Corporation (NASDAQ:RGEN). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $250.00 and a low of $172.00, we find $220.00. Given the previous closing price of $170.68, this indicates a potential upside of 28.9 percent. RGEN stock price is now -3.04% away from the 50-day moving average and -6.78% away from the 200-day moving average. The market capitalization of the company currently stands at $10.17B.

There are 3 analysts who have given it a hold rating, whereas 9 have given it a buy rating. Brokers who have rated the stock have averaged $214.27 as their price target over the next twelve months.

With the price target of $180, Deutsche Bank recently initiated with Hold rating for Repligen Corporation (NASDAQ: RGEN). On December 07, 2022, RBC Capital Mkts recently initiated its ‘Sector Perform’ rating on the stock quoting a target price of $190, while ‘UBS’ rates the stock as ‘Buy’.

In other news, Snodgres Jon, Chief Financial Officer sold 5,647 shares of the company’s stock on Feb 16. The stock was sold for $1,129,400 at an average price of $200.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 29,325 shares in the company, valued at $5.14 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 11, Chief Executive Officer Hunt Anthony sold 25,000 shares of the business’s stock. A total of $5,000,000 was realized by selling the stock at an average price of $200.00. This leaves the insider owning 178,265 shares of the company worth $31.25 million. Insiders disposed of 118,330 shares of company stock worth roughly $20.74 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.

There have been several recent changes in the stakes of large investors in RGEN stock. A new stake in Repligen Corporation shares was purchased by SUMITOMO MITSUI TRUST HOLDINGS, INC. during the first quarter worth $22,908,000. CERCANO MANAGEMENT LLC invested $11,597,000 in shares of RGEN during the first quarter. In the first quarter, APG ASSET MANAGEMENT N.V. acquired a new stake in Repligen Corporation valued at approximately $9,592,000. AMALGAMATED FINANCIAL CORP. acquired a new stake in RGEN for approximately $6,836,000. MITSUBISHI UFJ TRUST & BANKING CORP purchased a new stake in RGEN valued at around $5,258,000 in the second quarter. In total, there are 632 active investors with 93.40% ownership of the company’s stock.

Thursday morning saw Repligen Corporation (NASDAQ: RGEN) opened at $169.76. During the past 12 months, Repligen Corporation has had a low of $137.21 and a high of $262.26. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 2.50, and a quick ratio of 1.90. The fifty day moving average price for RGEN is $180.79 and a two-hundred day moving average price translates $188.04 for the stock.

The latest earnings results from Repligen Corporation (NASDAQ: RGEN) was released for Sep, 2022. According to the Medical Instruments & Supplies Company, earnings per share came in at $0.77, beating analysts’ expectations of $0.68 by 0.09. This compares to $0.50 EPS in the same period last year. The net profit margin was 23.20% and return on equity was 10.20% for RGEN. The company reported revenue of $186.76 million for the quarter, compared to $186.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.13 percent. For the current quarter, analysts expect RGEN to generate $184.56M in revenue.

Repligen Corporation(RGEN) Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.